Valmark Advisers Inc. Lowers Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Valmark Advisers Inc. lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,070 shares of the medical research company’s stock after selling 226 shares during the quarter. Valmark Advisers Inc.’s holdings in Thermo Fisher Scientific were worth $557,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Blue Zone Wealth Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 2.3% during the fourth quarter. Blue Zone Wealth Advisors LLC now owns 10,126 shares of the medical research company’s stock worth $5,268,000 after purchasing an additional 225 shares in the last quarter. Palouse Capital Management Inc. lifted its position in shares of Thermo Fisher Scientific by 71.3% in the fourth quarter. Palouse Capital Management Inc. now owns 2,802 shares of the medical research company’s stock valued at $1,458,000 after acquiring an additional 1,166 shares in the last quarter. MN Wealth Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 6.3% in the fourth quarter. MN Wealth Advisors LLC now owns 440 shares of the medical research company’s stock worth $229,000 after acquiring an additional 26 shares during the last quarter. Secured Retirement Advisors LLC raised its stake in Thermo Fisher Scientific by 19.4% in the 4th quarter. Secured Retirement Advisors LLC now owns 3,779 shares of the medical research company’s stock valued at $1,966,000 after purchasing an additional 613 shares during the last quarter. Finally, Strategic Financial Concepts LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $246,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.0 %

NYSE TMO opened at $532.58 on Tuesday. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The firm has a 50-day moving average price of $548.51 and a 200 day moving average price of $569.90. The stock has a market capitalization of $203.71 billion, a P/E ratio of 32.22, a P/E/G ratio of 3.18 and a beta of 0.77. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase program on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Bernstein Bank raised their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. Citigroup boosted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a research note on Friday, January 31st. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Barclays cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Finally, TD Cowen increased their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock valued at $11,231,699 in the last 90 days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.